Premium
Phytochemicals Isolated from Leaves of Chromolaena odorata : Impact on Viability and Clonogenicity of Cancer Cell Lines
Author(s) -
Kouamé Prevost BiKoffi,
Jacques Camille,
Bedi Gustave,
Silvestre Virginie,
Loquet Denis,
BarilléNion Sophie,
Robins Richard J,
Tea Illa
Publication year - 2013
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.4787
Subject(s) - chromolaena odorata , asteraceae , cytotoxicity , traditional medicine , viability assay , apoptosis , biology , botany , chemistry , biochemistry , in vitro , medicine , weed
The leaves of Chromolaena odorata (Asteraceae) are exploited extensively in West and Central African ethnopharmacy for the treatment of a wide range of conditions, despite this being a non‐native species established in the last 50 years. With the objective of seeking bioactive principles, the nonvolatile compounds, an ethanolic (80% v/v) extract was made and fractionated. From the hexane‐soluble fraction, three compounds were isolated. Two of these, 5‐hydroxy‐7,4′‐dimethoxyflavanone and 2′‐hydroxy‐4,4′,5′,6′‐tetramethoxychalcone, have previously been identified in C. odorata leaves. The third was fully characterised spectroscopically and found to be 1,6‐dimethyl‐4‐(1‐methylethyl)naphthalene (cadalene), not previously isolated from the Asteraceae. All three compounds were tested for their cytotoxicity and anticancer properties. 2′‐Hydroxy‐4,4′,5′,6′‐tetramethoxychalcone was found to be both cytotoxic and anticlonogenic at 20 µ m in cell lines Cal51, MCF7 and MDAMB‐468, and to act synergistically with the Bcl2 inhibitor ABT737 to enhance apoptosis in Cal51 breast cancer cells. Copyright © 2012 John Wiley & Sons, Ltd.